ViGenCell’s Immune Cell Therapies To Get A Boost From $85M IPO
IPO Priced At Top Of Stock Price Band
Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.
You may also be interested in...
South Korean pharma HK inno.N’s $500m IPO has drawn strong interest with subscriptions from institutional investors marking a record high. The IPO should help it speed up development of cell and gene therapies and beef up its vaccines business.
Only one last step remains before the approval of South Korea’s first home-grown COVID-19 vaccine as SK Bioscience’s SKYCovione (GBP510) receives positive assessments from review committees. Any nod, which could happen this week, would mark a milestone for the country's ambitions of becoming a global vaccine hub.
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.